Topics

Regeneron's bone disorder drug reduces lesions in mid-stage study

08:07 EST 9 Jan 2020 | Reuters

Regeneron Pharmaceuticals Inc said on Thursday its experimental treatment for a very rare genetic bone disorder showed a nearly 90% reduction in new lesions compared to placebo, in a mid-stage study.

Original Article: Regeneron's bone disorder drug reduces lesions in mid-stage study

NEXT ARTICLE

More From BioPortfolio on "Regeneron's bone disorder drug reduces lesions in mid-stage study"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...